Optimal use of antimalarials in treating cutaneous lupus erythematosus

American Journal of Clinical Dermatology

Volumn 6, Issue 1, 2005, Pages 1-11

  Wozniacka, Anna ^a   McCauliffe, Daniel P ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Rutland Skin Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPICILLIN; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CHLORPROMAZINE; CIMETIDINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DAPSONE; DILTIAZEM; GOLD; HYDROXYCHLOROQUINE; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; KAOLIN; MEPACRINE; METHOTREXATE; NEUROLEPTIC AGENT; PIMECROLIMUS; RETINOID; TACROLIMUS; THALIDOMIDE;

ABDOMINAL CRAMP; APLASTIC ANEMIA; ATRIOVENTRICULAR BLOCK; BIRTH DEFECT; BLOOD TOXICITY; CLAUSTROPHOBIA; CLINICAL FEATURE; CLINICAL TRIAL; DELUSION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRY SKIN; ERYTHEMA MULTIFORME; EXANTHEMATOUS PUSTULOSIS; EYE TOXICITY; FEELING OF INFERIORITY; GASTROINTESTINAL SYMPTOM; HAIR BLEACHING; HAIR DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMOLYSIS; HUMAN; JAUNDICE; KIDNEY DISEASE; LICHENOID ERUPTION; LIVER TOXICITY; LOSS OF AFFECTION; LUNG DISEASE; MOOD DISORDER; MUCOCUTANEOUS DISEASE; MUSCLE DISEASE; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROTOXICITY; NIGHTMARE; PARANOIA; PHOTOPHOBIA; PHOTOSENSITIVITY; PIGMENT DISORDER; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; PUSTULOSIS; RELAPSE; RETINA DISEASE; REVIEW; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SLEEP DISORDER; SMOKING; SYMPTOM; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VOMITING;

ANTIMALARIALS; CHLOROQUINE; DRUG INTERACTIONS; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, CUTANEOUS; SMOKING; TIME FACTORS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 14244249304     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200506010-00001     Document Type: Review

References (126)

1. Payne JF. A postgraduate lecture on lupus erythematosus. Clin J 1894; 4: 223-9
2. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: the Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 65-7
3. Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol Biopharm 1978; 16: 395-401
4. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 1974; 3: 103-8
5. McChesney EW, Rothfield NF. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7: 328-9
6. Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189: 425-7
7. Lipsker D, Piette JC, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190: 257-8
8. Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9: 92-5
9. Koranda FC. Antimalarials. J Am Acad Dermatol 1981; 4: 650-5
10. Sjolin-Forsberg G, Berne B, Blixt C, et al. Chloroquine phosphate: a long-term follow up of drug concentration in skin suction blister fluid and plasma. Acta Derm Venereol 1993; 73: 426-9
11. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985; 64: 285-95
12. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-5
13. Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis 1982; 8: 207-18
14. McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg 2001; 20: 14-26
15. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4
16. The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1997; 7: 80-5
17. Sontheimer RD, Provost TT. Cutaneous manifestations of lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore (MD): Williams & Wilkins, 1997: 569-23
18. Sontheimer RD, Thomas JR, Gilliam JM. Subacute cutaneous lupus erythematosus. Arch Dermatol 1979; 115: 1409-15
19. Cardinali C, Caproni M, Baenacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus: the Italian experience. Lupus 2000; 9: 417-23
20. Furner BB. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 1990; 29: 542-7
21. Ruzicka T, Bieber T, Meurer M. Subacute cutaneous lupus erythematosus: clinical aspects, immunology and therapy. Wien Klin Wochenschr 1987; 99: 802-7
22. Jessop S, Whitelaw D, Jordan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001; 1: CD 002954
23. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118: 412-6
24. Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 1997; 24: 569-72
25. Morgan KW, Callen JP. Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 2001; 28: 129-32
26. Harvey S, Pineda R, Shore JW, et al. Hypertrophic discoid lupus erythematosus of conjunctiva. Am J Ophthalmol 1999; 127: 604-5
27. Donzis PB, Insler MS, Buntin DM, et al. Discoid lupus erythematosus involving the eyelids. Am J Ophthalmol 1984; 98: 32-6
28. Pock L, Petrovska P, Becvar R, et al. Verrucous form of chilblain lupus erythematosus. J Eur Acad Dermatol Venereol 2001; 15: 448-51
29. Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33-51
30. Werth V, Franks A. Treatment of discoid skin lesions with azathioprine. Arch Dermatol 1986; 122: 746-7
31. Wallace DJ. Antimalarials: the "real" advance in lupus. Lupus 2001; 10: 385-7
32. Wallace DJ. Antimalarial therapies. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore (MD): Williams & Wilkins, 1997: 1117-40
33. Rahman P, Gladmann DD, Urowitz MB. Efficacy of antimalarial therapy in cutaneous lupus in smokers versus non-smokers. J Rheumatol 1998; 25: 1716-9
34. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42: 983-7
35. Miller RG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990; 9: 125-35
36. Polet T. The effects of lysosomotrophic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes. J Cell Physiol 1985; 122: 415-23
37. Wanwimolruk S, Wong SM, Coville PF, et al. Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol 1993; 36: 610-4
38. Hardy CJ, Palmer BP, Muir KR, et al. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 1998; 57: 451-5
39. Nagata C, Fujita S, Iwata H, et al. Systemic lupus erythematosus: a case-control epidemiologic study in Japan. Int J Dermatol 1995; 34: 333-7
40. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 243-63
41. Johansson E, Kanerva L, Niemi KM, et al. Diffuse soft tissue calcifications (calcinosis cutis) in patient with discoid lupus erythematosus. Clin Exp Dermatol 1988; 13: 193-6
42. Marzano AV, Kolesnikova LV, Gasparini G, et al. Dystrophic calcinosis cutis in subacute cutaneous lupus. Dermatology 1999; 90: 90-2
43. Wozniacka A, Robak E, Sysa-Jedrzejowska A, et al. The influence of chloroquine treatment on minimal erythema dose measurements in systemic lupus erythematosus patients [abstract]. J Invest Dermatol 2002; 3: 763
44. Nishijima C, Hatta N, Inaoki M, et al. Urticarial vasculitis in systemic lupus erythematosus: fair response to prednisolone/dapsone and persistent hypocomplementemia. Eur J Dermatol 1999; 9: 54-6
45. Malcangi G, Brandozzi G, Giangiacomi M, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003; 12: 63-6
46. Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol 2000; 41: 234-7
47. Krim E, Noblesse I, Beylot Barry M, et al. Bullous localization of a lupus erythematosus induced by radiotherapy. Ann Dermatol Venereol 2002; 129: 1307-9
48. Fowler Jr JF, Callen JP. Cutaneous mucinosis associated with lupus erythematosus. J Rheumatol 1984; 11: 380-3
49. Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus; a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033-41
50. Fox JN, Klapman MH, Rowe L. Lupus profundus in children: treatment with hydroxychloroquine. J Am Acad Dermatol 1987; 16: 839-44
51. Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 1993; 28: 634-70
52. Magana-Garcia M. Antimalarials for children [letter]. J Am Acad Dermatol 1994; 3: 510
53. Khamashta MA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus 1996; 5: S65-6
54. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double blind and placebo-controlled study. Lupus 2001; 10: 401-4
55. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2004; 50: 3056-7
56. Tett SE, Cutler DJ, Day RO, et al. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26: 303
57. Petri M. Thrombosis and systemic lupus erythematosus; the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191-3
58. Rynes RI. Antimalarials: is re-evaluation needed? J Clin Rheumatol 1998; 4: 50-1
59. Hobbs HE, Eadie SP, Somerville F. Ocular lesions after treatment with chloroquine. Br J Ophthalmol 1961; 45: 284-97
60. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 206-21
61. Lozier JR, Friedlaender MH. Complications of antimalarial therapy. Int Ophthalmol Clin 1989; 29: 172-8
62. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482-6
63. Mavrikakis I, Mavrikakis E. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Rheumatology 2004; 43: 1057-8
64. Araiza-Casillas R, Cardenas F, Morales Y, et al. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13: 621
65. Neubauer AS, Samari-Kermani K, Schaller U, et al. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 2003; 87: 902-8
66. Pluenneke AC, Blomquist PH. Utility of red Amsler grid screening in a rheumatology clinic. J Rheumatol 2004; 31: 1754-5
67. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-31
68. Sontheimer RD. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus. Arch Dermatol 2000; 136: 1044-9
69. Trenholme GM, Carson PE. Therapy and prophylaxis of malaria. JAMA 1978; 240: 2293-5
70. Custer RP. Aplastic anemia in soldiers treated with Atabrine (quinacrine). Am J Med Sci 1946; 212: 211-24
71. Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981; 20: 57-61
72. Schmid I, Anasetti C, Petersen FB, et al. Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine. Blut 1990; 61: 52-4
73. Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol 1985; 12: 863-5
74. Evans RL, Khalid S, Kinney JL. Antimalarial psychosis revisited. Arch Dermatol 1984; 120: 765-7
75. Genel F, Erermis S, Aksu G, et al. Quinacrine-induced psychiatric disturbances in a child with common variable immunodeficiency and chronic giardiasis. Hum Psychopharmacol 2002; 17: 357-9
76. Tristano AG, Falcon L, Wilson M, et al. Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus. Rheum Int 2004; 24: 315-6
77. Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. Acta Derm Venereol 1999; 79: 333
78. Jimenez-Alonso J, Tercedor J, Reche I. Antimalarial drugs and pruritus in patients with lupus erythematosus [letter]. Acta Derm Venereol 2000; 80: 458
79. Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol 2004; 50: 650-1
80. Litt JZ. Litt's drug eruption manual. 9th ed. New York: Parthenon Publishing, 2003: 91, 92, 219, 220
81. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a re-examination. Semin Arthritis Rheum 1989; 18: 282-97
82. Metayer I, Balguerie X, Courville P, et al. Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 2001; 128: 729-31
83. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1231-3
84. Verny C, Gennes C, Sebastien P, et al. Heart conduction disorders in long-term treatment with chloroquine: two new cases. Presse Med 1992; 21: 800-4
85. Physicians desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 3008
86. Physicians desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 2984
87. Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001; 19: 420-4
88. Harris L, Downar E, Shaikh NA, et al. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiol 1988; 4: 295-300
89. Seidman P, Albertioni F, Beck O, et al. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 830-3
90. McElnay JC, Sidahmed AM. D'Arcy PF. Examination of the chloroquine-kaolin drug absorption interaction using the buccal partitioning model. J Clin Hosp Pharm 1982; 7: 269-73
91. Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987; 27: 813-6
92. Algharably N, Owler D, Lamb JF. The rate of uptake of cardiac glycosides into human cultured cells and the effects of chloroquine on it. Biochem Pharmacol 1986; 35: 3571-81
93. Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 1996; 712: 179-89
94. Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol 2000; 42: 645-52
95. Makin AJ, Wendon J, Fitt S, et al. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994; 35: 569-70
96. Fries JF, Singh G, Lenert L, et al. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611-9
97. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Opthalmol 2002; 133: 649-56
98. Fox R, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5: S31-6
99. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221-5
100. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27: 2927-31
101. Desta M, Tadesse A, Gebre N. et al. Controlled trial of hydroxychloroquine in schizophrenia. J Clin Psychopharmacol 2002; 22: 507-10
102. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11: 71-81
103. Landewe RB, Miltenburg AM, Breedveld FC, et al. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353-7
104. Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med 1983; 18: 19-24
105. Sjolin-Forsberg G, Berne B, Eggelte TA, et al. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995; 75: 228-31
106. Olczyk K, Drozdz M, Kucharz E, et al. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus. Med Interne 1984; 22: 221-5
107. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5: S4-S10
108. Ruzicka T, Printz M. Arachidonic acid metabolism in guinea pig skin: effects of chloroquine. Agents Actions 1982; 12: 527-9
109. Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 803-8
110. Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003; 139: 50-4
111. Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148: 353-6
112. Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12: 50-2
113. Gerdsen R, Wenzel I, Uerlich M, et al. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology 2002; 205: 416-8
114. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43 (11): 1383-5
115. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51 (3): 407-10
116. Hall RP, Lawley TJ, Smith HR, et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165-70
117. Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35: 313-5
118. Neri R, Mosca M, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. Lupus 1999; 8: 240-3
119. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991; 24: 49-52
120. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513-8
121. Arbiser JL, Moschella SL. Clofazimine: A revive of its medical uses and mechanisms of action. J Am Acad Dermatol 1995; 32: 241-7
122. Tsokos GC, Caughman SW, Kleppel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1985; 121: 1323-5
123. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998; 18: 59-62
124. Bohm I, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194: 307-8
125. Peter RU, Ruzicka T. Cyclosporin A in the therapy of inflammatory dermatoses. Hautarzt 1992; 43: 687-4
126. Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986; 115: 211-6